公开(公告)号：US12031135B2

公开(公告)日：2024-07-09

申请号：US17813493

申请日：2022-07-19

申请人： Baylor College of Medicine

发明人： Vivekkumar B. Patel ,  Hongran Wang ,  Vivek P. Singh ,  Erin Lynn Reineke ,  Megumi Mathison ,  Austin J. Cooney ,  Todd Rosengart

IPC分类号： C12N15/86 ,  A61K9/00 ,  A61K31/47 ,  A61K31/713 ,  A61K38/17 ,  A61K48/00 ,  C07K14/47 ,  C07K14/82 ,  C12N5/077 ,  C12N15/113

CPC分类号： C12N15/113 ,  A61K9/0019 ,  A61K31/47 ,  A61K31/713 ,  A61K38/1709 ,  A61K48/0058 ,  C07K14/4702 ,  C07K14/4746 ,  C07K14/82 ,  C12N5/0657 ,  C12N15/1135 ,  C12N15/86 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2320/31 ,  C12N2501/60 ,  C12N2710/10043 ,  C12N2740/15043 ,  C12N2310/14 ,  C12N2310/531

摘要： Embodiments of the disclosure include methods and compositions for in situ cardiac cell regeneration, including transdifferentiation of cardiac cells to cardiomyocytes. In particular embodiments, in situ cardiac cell regeneration encompasses delivery of p63 shRNA and one or both of Hand2 and myocardin, and in specific embodiments further includes one or more of Gata4, Mef2c, and Tbx5. In specific aspects of the disclosure, adult cardiac fibroblasts are reprogrammed into cardiomyocytes using viral vectors that harbor p63 shRNA and one or both of the transcription factors Hand2 and myocardin.

公开(公告)号：US11920138B2

公开(公告)日：2024-03-05

申请号：US16507977

申请日：2019-07-10

申请人： The Trustees of Columbia University in the City of New York

发明人： Antonio Iavarone ,  Anna Lasorella ,  Raul Rabadan

IPC分类号： C12N15/62 ,  C07K14/47 ,  C07K14/71 ,  C07K14/82 ,  C07K16/18 ,  C07K16/28 ,  C12N9/12 ,  C12Q1/6886 ,  G01N33/574

CPC分类号： C12N15/62 ,  C07K14/47 ,  C07K14/71 ,  C07K14/82 ,  C07K16/18 ,  C07K16/2863 ,  C12N9/12 ,  C12Q1/6886 ,  G01N33/57492 ,  C07K2319/00 ,  C07K2319/73 ,  C12Q2600/158 ,  G01N2333/91205

摘要： The invention discloses oncogenic fusion proteins. The invention provides methods for treating gene-fusion based cancers.

公开(公告)号：US20240060070A1

公开(公告)日：2024-02-22

申请号：US18267223

申请日：2021-12-15

申请人： Cambridge Enterprise Limited ,  International Centre for Genetic Engineering and Biotechnology

发明人： Sudhakaran PRABAKARAN

IPC分类号： C12N15/113 ,  A61K31/4155 ,  A61K31/4709 ,  C07K14/82 ,  C12N15/86

CPC分类号： C12N15/1135 ,  A61K31/4155 ,  A61K31/4709 ,  C07K14/82 ,  C12N15/86 ,  C12N2310/11 ,  C12N2740/15043

摘要： The present application features methods of treating a cancer associated with a genetic variant. The genetic variant is also present within a novel open reading frame (nORF) associated with the gene in which the variant leads to increased or reduced expression of the variant nORF.

公开(公告)号：US11897933B2

公开(公告)日：2024-02-13

申请号：US17345390

申请日：2021-06-11

申请人： The United States of America,as represented by the Secretary,Department of Health and Human Services

发明人： Eric Tran ,  Yong-Chen Lu ,  Anna Pasetto ,  Paul F. Robbins ,  Steven A. Rosenberg ,  Zhili Zheng

IPC分类号： C07K14/725 ,  C07K14/82 ,  G01N33/574 ,  A61P35/00 ,  C12N15/85 ,  A61K38/00

CPC分类号： C07K14/7051 ,  A61P35/00 ,  C07K14/82 ,  C12N15/85 ,  G01N33/57407 ,  A61K38/00 ,  C12N2015/8518 ,  G01N2333/7051

摘要： Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

公开(公告)号：US20240002547A1

公开(公告)日：2024-01-04

申请号：US18348229

申请日：2023-07-06

申请人： AEBI LTD.

发明人： llan MORAD ,  Hanan ITZHAKI

IPC分类号： C07K17/08 ,  C07K14/82 ,  A61K47/60 ,  A61P35/00 ,  C07K14/47 ,  C07K7/08 ,  A61K47/62 ,  A61K47/64 ,  C07K14/33 ,  C07K14/705

CPC分类号： C07K17/08 ,  C07K14/82 ,  A61K47/60 ,  A61P35/00 ,  C07K14/4748 ,  C07K7/08 ,  A61K47/62 ,  A61K47/6415 ,  C07K14/33 ,  C07K14/70532 ,  C07K2319/33 ,  C07K2319/00 ,  C07K2319/40 ,  C07K2319/55 ,  A61K38/00

摘要： The present invention provides constructs comprising a plurality of peptides capable of targeting at least two different extracellular tumor antigens and a toxin, optionally connected to an organic scaffold. Use of such constructs in treating cancer are provided as well. The invention also provides particular peptides binding certain extracellular tumor antigens as well as toxins having antitumor activity.

公开(公告)号：US11840561B2

公开(公告)日：2023-12-12

申请号：US17541619

申请日：2021-12-03

申请人： The United States of America, as represented by the Secretary, Department of Health and Human Services

发明人： Eric Tran ,  Yong-Chen Lu ,  Anna Pasetto ,  Paul F. Robbins ,  Steven A. Rosenberg ,  Zhili Zheng

IPC分类号： C07K14/725 ,  C07K14/82 ,  G01N33/574 ,  A61P35/00 ,  C12N15/85 ,  A61K38/00

CPC分类号： C07K14/7051 ,  A61P35/00 ,  C07K14/82 ,  C12N15/85 ,  G01N33/57407 ,  A61K38/00 ,  C12N2015/8518 ,  G01N2333/7051

摘要： Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

公开(公告)号：US20230357410A1

公开(公告)日：2023-11-09

申请号：US17312258

申请日：2019-12-20

申请人： Zhejiang Shimai Pharmaceutical Co.,Ltd.

发明人： Weizao Chen ,  Yanping Wang ,  Zuoxiang Xiao

IPC分类号： A61K39/00 ,  A61P35/00 ,  C07K14/71 ,  C07K14/82 ,  C07K16/28

CPC分类号： C07K16/2863 ,  A61P35/00 ,  C07K14/71 ,  C07K14/82 ,  C07K16/2809 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/50

摘要： The present invention provides recombinant bispecific antibodies designed to bind to a surface antigen on target cells and to an activating component on immune cells such as T cells. The bispecific antibodies comprise two polypeptide chains that contain Fv and Fab as antigen¬ binding fragments and a modified Fc region to facilitate heterodimer formation. In one embodiment, the bispecific antibodies further comprise protease cleavage sites and/or motifs that would cause steric occlusion of the antigen binding sites so that the antibodies would be activated only in a specific environment, e.g. in the vicinity of a tumor. In another embodiment, the bispecific antibodies comprise modified sequences that confer reduced binding affinity to CDS and/or cross-reactive binding to CDS on cells from different species.

公开(公告)号：US11732017B2

公开(公告)日：2023-08-22

申请号：US17240260

申请日：2021-04-26

申请人： The USA, as represented by the Secretary, Dept. of Health and Human Services

发明人： Jeffrey Schlom ,  Kwong-Yok Tsang

IPC分类号： C07K14/47 ,  C07K14/82 ,  A61K38/19 ,  A61K38/20 ,  A61K38/21 ,  A61K38/22 ,  A61K31/00 ,  A61K45/06 ,  A61K39/00 ,  A61K39/39 ,  C12N7/00 ,  A61K38/00

CPC分类号： C07K14/4727 ,  A61K31/00 ,  A61K38/191 ,  A61K38/193 ,  A61K38/195 ,  A61K38/20 ,  A61K38/217 ,  A61K38/22 ,  A61K39/00117 ,  A61K39/39 ,  A61K45/06 ,  C07K14/82 ,  C12N7/00 ,  A61K38/00 ,  A61K2039/5154 ,  A61K2039/53 ,  A61K2039/55588 ,  C07K2319/00 ,  C12N2710/24143 ,  C12N2710/24171 ,  A61K38/20 ,  A61K2300/00 ,  A61K38/217 ,  A61K2300/00 ,  A61K38/191 ,  A61K2300/00 ,  A61K38/195 ,  A61K2300/00 ,  A61K38/193 ,  A61K2300/00 ,  A61K38/22 ,  A61K2300/00 ,  A61K31/00 ,  A61K2300/00

摘要： The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and/or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.

公开(公告)号：US20230241065A1

公开(公告)日：2023-08-03

申请号：US17817619

申请日：2022-08-04

申请人： FOUNDATION MEDICINE, INC.

发明人： Sean R. DOWNING ,  Matthew J. HAWRYLUK ,  Doron LIPSON ,  Alexander N. PARKER ,  Philip James STEPHENS

IPC分类号： A61K31/517 ,  C07K14/82 ,  C12N9/14 ,  C12Q1/6886 ,  A61K31/404 ,  A61K31/4412 ,  A61K31/444 ,  A61K31/47 ,  A61K31/513 ,  C12N15/113

CPC分类号： A61K31/517 ,  A61K31/47 ,  A61K31/404 ,  A61K31/444 ,  A61K31/513 ,  A61K31/4412 ,  C07K14/82 ,  C12N9/14 ,  C12N15/1135 ,  C12Q1/6886 ,  C07K2319/00 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Q2600/158

摘要： Novel RET fusion molecules and uses are disclosed.

公开(公告)号：US11680092B2

公开(公告)日：2023-06-20

申请号：US16765084

申请日：2018-11-20

申请人： Turun yliopisto

发明人： Eleonora Mäkelä ,  Jukka Westermarck

IPC分类号： G01N33/00 ,  C07K14/82 ,  C07K16/18 ,  C07K16/30 ,  C12Q1/6886 ,  G01N33/574

CPC分类号： C07K14/82 ,  C07K16/18 ,  C07K16/30 ,  C12Q1/6886 ,  G01N33/57496 ,  C07K2317/34 ,  C12Q2600/118 ,  C12Q2600/156

摘要： The present invention relates to a novel cancer-associated biomarker and different applications and uses thereof. More specifically, the invention relates to a novel splice variant of CIP2A denoted as NOCIVA, as well as binding bodies such as probes, amplification primers, and antibodies specific for the same. Also provided are various methods for detecting and prognosing cancer on the basis of said splice variant, and a kit for use in said methods.